Overview

* Castle Biosciences Q2 2025 revenue of $86.2 mln smashes analyst expectations

* The medical testing provider raises full-year 2025 revenue guidance to $310-320 mln

* Q2 test report volume increased 6% yr/yr

Outlook

* Castle Biosciences ( CSTL ) raises 2025 revenue guidance to $310 mln-$320 mln

* Previse acquisition and SciBase collaboration expected to support future growth

Result Drivers

* CORE TEST GROWTH - DecisionDx-Melanoma and TissueCypher test volumes increased significantly, driving revenue performance

* NON-COVERAGE IMPACT - Revenue affected by Novitas LCD non-coverage of DecisionDx-SCC and discontinuation of IDgenetix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $86.19 $71.40

Revenue mln mln (9

Analysts

)

Q2 Net $4.52

Income mln

Q2 $90.44

Operatin mln

g

Expenses

Q2 -$4.25

Operatin mln

g Income

Q2 -$143,00

Pretax 0

Profit

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Castle Biosciences Inc ( CSTL ) is $36.00, about 59.3% above its August 1 closing price of $14.65

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)